Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Authors

Bradley Rivotto

Publication/Presentation Date

12-2016

Volume

128

Issue

22

First Page

976

Last Page

976

Published In/Presented At

https://doi.org/10.1182/blood.V128.22.976.976

Disciplines

Medicine and Health Sciences

Department(s)

Fellows and Residents

Document Type

Article